ANN ARBOR, MI — Oral pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) gained Food and Drug Administration approval in 2012, and many commentators hailed the therapy as a “once-in-a-generation” advance.
HOUSTON — After a decade of dramatically rising rates of hepatocellular carcinoma (HCC) among veterans, aggressive treatment of hepatitis C infections (HCV) appears poised to turn the tide.
SEATTLE — Pulmonary infections remain more common in patients with human immunodeficiency virus (HIV), compared with those who are uninfected. Surmising that an increase in chronic lung diseases among aging HIV positive patients could contribute to the risk, a University… Read More
Pre-infection Immunological Health Achieved in Some Cases By Annette M. Boyle SAN ANTONIO — For years, clinicians have not recommended treating human immunodeficiency virus (HIV) patients with antiretroviral therapy (ART) before they saw a significant drop in T-cell levels. Starting… Read More
Subhead: Post-operative Mortality Rates Low Among ART Users By Annette M. Boyle WEST HAVEN, CT — Historically, high post-operative mortality rates among HIV-infected patients caused many physicians and patients to defer or avoid surgery all together. For today’s veterans with… Read More
Raymond Schinazi, PhD, Hon DSc, still remembers how the patients lined the corridors. They were all too thin, too pale and much too weak.
Amid all the outcry over the high cost of new hepatitis C therapies, including congressional hearings, a simple fact has been overlooked: The VA expects to save money in the long run because of the drugs’ high cure rates. By… Read More
Alliance Research Not Limited by Private-Sector Restraints By Annette M. Boyle BETHESDA, MD – In celebration of its second anniversary, the John P. Murtha Cancer Center at the Walter Reed National Military Medical Center, announced plans to substantially expand its… Read More
VA Suggests High Price Could Be Offset Future Savings
By Brenda L. Mooney BOSTON – Rates of serologic testing for hepatitis B (HBV) at the VA fail to meet levels recommended by the American Association for the Study of Liver Diseases (AASLD) practice guideline, according to new research. Researchers… Read More
Clinicians Find Advances ‘Mind-Boggling’ By Annette M. Boyle ATLANTA – Therapeutic options for patients with human immunodeficiency virus (HIV) continue to expand, enabling more veterans to begin treatment with fewer adverse side effects and far less complicated regimens than even… Read More
By Annette M. Boyle WASHINGTON – While commercial insurers responded to the approval of the breakthrough drug sofosbuvir for hepatitis C (HCV) by implementing prescribing restrictions, limiting use to the sickest patients and charging higher co-pays because of the drug’s… Read More
BOSTON – Patients with disfiguring and debilitating scars suffer poor cosmetic outcomes, restricted motion, pain and itching, despite traditional therapy such as expert wound care. A consensus report published earlier this year in JAMA Dermatology discusses a breakthrough within the… Read More